Novo Nordisk to slash prices of weightloss drugs in US / Photo: © GETTY IMAGES NORTH AMERICA/AFP/File
-
China hails 'our era' as Wu Yize's world snooker triumph goes viral
-
Ex-model accuses French scout of grooming her for Epstein
-
Timberwolves eclipse Spurs as Knicks rout Sixers
-
Taiwan leader says island has 'right to engage with the world'
-
Yoko says oh no to 'John Lemon' beer
-
Bayern's Kompany promises repeat fireworks in PSG Champions League semi
-
A coaching great? Luis Enrique has PSG on brink of another Champions League final
-
Top five moments from the Met Gala
-
Brunson leads Knicks in rout of Sixers
-
Retiring great Sophie Devine wants New Zealand back playing Tests
-
Stocks sink amid fears over US-Iran ceasefire
-
G7 trade ministers set to meet but not discuss latest US tariff threat
-
Sherlock Holmes fans recreate fateful duel at Swiss falls
-
Premier League losses soar for clubs locked in 'arms race'
-
'Spreading like wildfire': Fiji grapples with soaring HIV cases
-
For Israel's Circassians, food and language sustain an ancient heritage
-
'Super El Nino' raises fears for Asia reeling from Middle East conflict
-
Trouble in paradise: Colombia tourist jewel plagued by violence
-
Death toll in Brazil small plane crash rises to three
-
Pulitzers honor damning coverage of Trump and his policies
-
LA fire suspect had grudge against wealthy: prosecutors
-
US-Iran ceasefire on brink as UAE reports attacks
-
Stars shine at Met Gala, fashion's biggest night
-
Birthday girl, 10, among dead in Colombia monster truck crash
-
Blake Lively, Justin Baldoni agree to end lengthy legal battle
-
Dolly Parton cancels Las Vegas shows over health concerns
-
Wu Yize: China's 'priest' who conquered the snooker world
-
China's Wu Yize wins World Snooker Championship for first time
-
Broadway theater blaze forces 'Book of Mormon' to close
-
Advantage Arsenal as Man City held in six-goal Everton thriller
-
Roma hammer Fiorentina to remain in Champions League hunt
-
MLB Tigers star pitcher Skubal to undergo elbow surgery
-
Oil prices jump on Hormuz tensions as US indices retreat from records
-
No.6 Morikawa withdraws from final PGA Championship tuneup
-
Ukraine and Russia declare separate truces
-
Arteta warns Atletico will face Arsenal 'beasts' in Champions League
-
OpenAI co-founder under fire in Musk trial over $30 bn stake
-
Amazon to ship stuff for any business, not just its own merchants
-
Swastikas daubed on NY Jewish homes, synagogues: police
-
Colombian guerrillas offer peace talks with Petro successor
-
Britney Spears admits reckless driving in plea deal
-
Rohit, Rickelton keep Mumbai in IPL playoff hunt
-
Health emergency on the MV Hondius: what we know
-
US downs Iran missiles and drones, destroys six of Tehran's boats
-
Simeone laughs off 'cheaper' Atletico hotel switch before Arsenal clash
-
Rohit, Rickelton keep Mumbai in the hunt
-
What is hantavirus, and can it spread between humans?
-
Britney Spears admits to reckless driving in plea deal
-
Two dead as car ploughs into crowd in Germany's Leipzig
-
Ujiri hired as president of NBA's Mavericks
Novo Nordisk to slash prices of weightloss drugs in US
Danish drugmaker Novo Nordisk, which is struggling with competition for its anti-obesity treatments, said Tuesday that it will sharply cut prices for its flagship drugs in the US, announcing a 50 percent cut for Wegovy and 35 percent for Ozempic.
"This decision applies to all doses of these medicines and reflects Novo Nordisk's commitment to enhancing affordability for patients and both public and private payers dealing with the complexities of the evolving US healthcare system," the company said in a statement.
Effective January 1, 2027, the list price will be $675 for a month's worth of Wegovy, which currently costs around $1,350 a month.
Ozempic and Rybelsus, treatments that each currently come to about $1,000, will also be priced $675.
Novo Nordisk said the price reduction is meant to make it possible to reach more patients.
"Lowering the list price of Wegovy and Ozempic is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States," Jamey Millar, executive vice president of Novo Nordisk's US Operations, said.
In early February, Novo Nordisk vowed legal against US chain Hims & Hers for offering a copycat of the new pill version of Wegovy.
Limited production capacity for the blockbuster drug led the FDA to temporarily allow pharmacies to create so-called "compound" or copycat versions of Wegovy and Ozempic, an analogue used to treat diabetes.
That authorisation expired last May 22 but Novo Nordisk has complained of copycat versions of its drugs still being available.
Ozempic is an injectable anti-diabetic treatment that became popular on social media for its slimming properties.
Wegovy, which has the same active ingredient as Ozempic in a different dose, is a weight-loss drug and is also available in pill form.
Both treatments use analogues of the hormone GLP-1, which regulates blood glucose levels and appetite.
Shares in Novo Nordisk have taken a beating in recent weeks after it warned in early February of lower sales revenue in the United States as intensified competition pushes down prices.
They fell 3.8 percent in afternoon trading in Copenhagen.
L.Maurer--VB